Security key
24823R105
Denali Therapeutics Inc. - Common Stock (DNLI)
CUSIP: 24823R105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 156,230,240
- Total 13F value
- $3,998,691,804
- Share change
- +8,837,738
- Put/Call ratio
- 94%
- SEC-reported price per share
- $25.72
- Number of holders
- 293
- Value change
- +$251,115,055
- Number of buys
- 174
- Number of sells
- 95
- Shares outstanding
- 159,469,733
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
293
Top holders
10
DNLI full security history
Ownership snapshot
Full 13F holder table
Denali Therapeutics Inc. SEC filings
Denali Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of DNLI - Denali Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-6 of 15 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
10%
BAILLIE GIFFORD & CO
7.5%
BlackRock, Inc.
7.2%
FMR LLC
4.2%
WELLINGTON MANAGEMENT GROUP LLP
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
10%
|
$416,124,546
16,178,963 shares
|
+$197,010,076 | 30 Jun 2026 |
| BAILLIE GIFFORD & CO |
13D/G
13F
Company
|
7.5%
|
$307,138,706
11,960,230 shares
|
-$9,083,042 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.2%
from 13D/G
|
$250,261,131
13,034,434 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
4.2%
|
$128,121,587
6,672,999 shares
|
-$35,777,146 | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
3.9%
|
$82,251,923
5,664,733 shares
|
$0 | 30 Jun 2025 |
| Capital Research Global Investors |
13D/G
13F
Company
|
3.8%
|
$90,373,982
5,477,211 shares
|
$0 | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
293
Shares
156,230,240
Rows available
293
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
268
Q2 2026 holders
293
Holder diff
25
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|